Skip to main content

Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection

Clinuvel pharmaceuticals

ISIN: AU000000CUV3 , WKN: A0JEGY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


High Growth Tech Stocks To Watch In December 2025

2025-12-15
As the Australian market navigates a mixed landscape with tech stocks showing resilience amidst broader sector fluctuations, investors are keenly observing how economic indicators and global events influence small-cap performance. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to changing market dynamics.

Clinuvel Pharmaceuticals (ASX:CUV) Is Up 6.2% After Expanding Singapore Peptide R&D Hub - Has The Bull Case Changed?

2025-12-11
Earlier in December 2025, CLINUVEL PHARMACEUTICALS LTD announced a major expansion of its VALLAURIX Research, Development and Innovation Centre in Singapore, backed by the Singapore Economic Development Board, to accelerate liquid controlled-release peptide drug development and integrate advanced formulation and analytical capabilities. This five-year investment is a core part of Clinuvel’s vertical integration plan, positioning the Singapore hub as a global centre for next‑generation...

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check After Vallaurix R&D Expansion in Singapore

2025-12-09
Clinuvel Pharmaceuticals (ASX:CUV) is back on investor radars after announcing a major expansion of its Vallaurix research hub in Singapore, a five year push to deepen peptide therapy innovation and vertical integration. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that story, with a 17.92% 1 month share price return helping lift Clinuvel to A$12.70, even though the 3 year total shareholder return remains sharply negative. As a result, momentum is...

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies

2025-12-08
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of l

Exploring 3 High Growth Tech Stocks in Australia

2025-12-07
As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.

ASX Growth Companies With Insider Ownership Up To 38%

2025-12-01
The Australian market recently faced a setback with an ASX announcement outage, affecting numerous companies and causing a slight downturn in the indices. In such fluctuating conditions, growth companies with high insider ownership can be appealing as they often signal confidence from those who know the business best.

High Growth Tech Stocks In Australia To Watch

2025-12-01
The Australian market recently experienced technical issues with the ASX announcements outage, affecting several companies and contributing to a slight downturn in the S&P/ASX 200 index. In this environment, investors may be keen to identify high-growth tech stocks that demonstrate resilience and potential for expansion despite broader market challenges.

High Growth Tech Stocks In Australia For November 2025

2025-11-26
As the Australian market navigates a period of mixed sentiment, with the S&P/ASX 200 (XJO) rebounding to 8,600 points despite inflation climbing to 3.8%, investors are closely watching sectors like IT which recently lagged behind materials. In this environment, identifying high-growth tech stocks requires careful consideration of their resilience and potential catalysts for growth amidst broader economic fluctuations and sector-specific challenges.

Exploring High Growth Tech Stocks in Australia This November 2025

2025-11-16
As Australian shares brace for a challenging day with the ASX 200 futures indicating a significant drop, the market sentiment has been further unsettled by both domestic political shifts and international economic disruptions. In this climate, identifying high growth tech stocks requires careful consideration of their resilience to broader market volatility and their potential to capitalize on evolving technological trends amidst uncertain conditions.

ASX Growth Companies With Insider Stakes Up To 38%

2025-11-02
The Australian stock market is showing resilience, with shares gaining even as U.S. markets face volatility due to ongoing trade discussions and mixed earnings reports. In this environment, growth companies with high insider ownership can be particularly appealing, as insider stakes often signal confidence in a company's future prospects amidst broader market fluctuations.